atai Life Sciences to Participate in September Investor Conferences

atai Life Sciences to Participate in September Investor Conferences

Atai Life Sciences (NASDAQ: ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that its management is scheduled to participate in upcoming September investor conferences.

Details of the Company's participation are as follows:

Cantor Global Healthcare Conference 2025

Format: Fireside Chat
Date: Friday, September 5 th at 8:35 a.m. ET
Location: New York, NY

H.C. Wainwright 27 th Annual Global Investment Conference

Format: Fireside Chat
Date and Time: Monday, September 8 th at 11:30 a.m. ET
Location: New York, NY

TD Cowen 5 th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Format: Fireside Chat
Date and Time: Wednesday, September 17 th at 10:00 a.m. ET
Location: Virtual

The webcasts for the fireside chat will be available on atai's website under Events on the Investors section of the atai website. Replays will be available following the live events.

About atai Life Sciences
atai is a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. Our pipeline of psychedelic-based therapies includes BPL-003 (intranasal mebufotenin benzoate) for treatment-resistant depression (TRD), which is being advanced through a strategic investment with Beckley Psytech Limited; VLS-01 (buccal film DMT) also for TRD; and EMP-01 (oral R-MDMA) for social anxiety disorder. All three programs are in Phase 2 clinical development. We are also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD. These programs aim to address the complex nature of mental health providing commercially scalable interventional psychiatry therapies that can integrate seamlessly into healthcare systems. For the latest updates and to learn more about our mission, visit www.atai.com or follow us on LinkedIn .

Contact Information
Investor Contact:
IR@atai.com

Media Contact:
PR@atai.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ATAI:US
The Conversation (0)
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

Atai Life Sciences (NASDAQ: ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team will participate in the Jefferies Global Healthcare Conference being held from June... Keep Reading...
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors

atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors

Atai Life Sciences (NASDAQ: ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai's supervisory... Keep Reading...
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H'24; Phase 2 study in TRD patients anticipated to initiate around YE'24 Beckley Psytech's Phase 2a study of BPL-003 in TRD patients showed rapid and durable antidepressant effects; Phase 2b topline data expected in 2H'24... Keep Reading...
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to SSRIs in patients with Treatment Resistant Depression. Initial results from the recently completed monotherapy Part 1 of the study were shared in March 2024 , and showed that a single... Keep Reading...

Latest Press Releases

Related News